Specialty Billing Built for Rheumatology Practices

Each biologic has a specific HCPCS J-code and billing unit, and the drug is billed in multiples of that unit. Infliximab (Remicade) is J1745 billed per 10 mg (a 100 mg vial = 10 units), abatacept (Orencia) is J0129 per 10 mg, tocilizumab (Actemra) is J3262 per 1 mg, rituximab (Rituxan) is J9312 per 10 mg, certolizumab pegol (Cimzia) is J0717 per 1 mg, and golimumab (Simponi Aria IV) is J1602 per 1 mg. Branded biologics use the J-code while biosimilars use separate Q-codes (e.g. infliximab biosimilars use Q5103/Q5104/Q5121), and billing the wrong one causes denials. We verify branded vs biosimilar, calculate units from the actual vials used, and bill the J-code on the same claim as the 96365 administration so both the drug and the administration are paid.

The JW modifier reports the amount of a drug or biological discarded and not administered to any patient, and it applies only to single-dose or single-use vials — never to multi-dose vials. The administered amount is billed on one line and the discarded amount is billed on a separate line with the JW modifier, in multiples of the HCPCS billing unit. The JZ modifier attests that no drug was discarded from a single-dose container and is required when no waste occurred. The medical record must document the dose administered, the discarded amount, and the date and time of administration. We apply JW and JZ correctly on every biologic infusion so waste is reimbursed where appropriate and the practice is protected from recoupment for inappropriate JW billing on multi-dose vials.

The drug administration infusion codes (96365–96368) are valued to include a baseline E/M, so a routine E/M on the same day is not separately billable. However, a significant, separately identifiable E/M — for example evaluating a new infusion reaction, a new complaint, or a change in disease activity — may be billed with modifier 25 appended to the E/M code. A different diagnosis is not strictly required, but the documentation must support that the E/M was distinct and above the routine work bundled into the infusion. We append modifier 25 only when the E/M is genuinely separate, with supporting documentation, so the E/M is paid rather than denied as bundled into the infusion administration.

High-cost biologics — often $1,000 to $10,000 or more per infusion — require prior authorization, step therapy, and medical-necessity documentation before the infusion is scheduled, or the entire claim (drug and administration) is denied. We verify each payer’s biologic policy, confirm step-therapy sequencing (e.g. failed conventional DMARDs before a biologic), submit the prior-authorization request with the supporting diagnosis and clinical records, and only schedule the infusion once authorization is secured. For Medicare Part B, we confirm the biologic is covered under the LCD/NCD and that the diagnosis supports medical necessity, so the J-code drug and the 96365 administration are both reimbursed.

Arthrocentesis codes are selected by joint size and whether ultrasound guidance was used: 20600 is a small joint, 20605 is an intermediate joint (wrist, elbow, ankle, TMJ, AC joint) without ultrasound, and 20610 is a major joint (shoulder, hip, knee) without ultrasound; 20604, 20606, and 20611 are the with-ultrasound counterparts. Only one unit of the arthrocentesis code is reported per joint per session, regardless of how many aspirations or injections are performed on that same joint. For different joints in the same session, multiple units are reported with modifier 59; for bilateral paired joints, modifier 50 (or RT/LT per payer policy) is appended; and a significant, separately identifiable E/M same day is billed with modifier 25. The injected drug (other than local anesthetic) is reported separately with its J-code. We apply the correct joint-size code, laterality, and modifiers so arthrocentesis revenue is captured correctly.